Equity Research Medical Distribution

Should You Buy VNOV Stock in 2026?

By CirclFi Research Team · · Updated · 9/13 models active

According to the CirclFi Deep Alpha Valuation Engine, VNOV (VNOV) carries a solid Quality of Company rating of 5.6/10. Trading at $1.38, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 9 CirclFi valuation models project upside for VNOV (VNOV) at $1.38 — the model consensus leans bearish, with a Quality Score of 5.6/10 and Value-Trap risk of 30/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 9 of 9 models suggest overvaluation — majority bearish
  • Quality Score: 5.6/10 — Moderate — mixed signals
  • Value Trap Risk: 30/100 — Low — manageable risk
  • Fair Value Range: $0.03 – $1.07 (3547% spread)

Bullish Models

0 / 9

Bearish Models

9 / 9

Quality Score

5.6 /10

Moderate — mixed signals

Value Trap Risk

30 /100
Low

Low — manageable risk

Model Consensus

9 /13
Active Models

Avg. confidence: 40%

What Is the Investment Case for VNOV (VNOV) in 2026?

What Is the Bull Case vs the Bear Case for VNOV (VNOV)?

Bull case versus bear case for VNOV (VNOV) at $1.38, derived from 9 active CirclFi valuation models on 2026-08-27.
Bull case Bear case — $0.03 target (-97.9%)
No active model projects meaningful upside for VNOV at $1.38. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.03 (-97.9%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +75.5% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

How Does VNOV Compare to Its Medical Distribution Peers?

FOCL EDAP TMS S.A.
5.8
SNYR Synergy CHC Corp.
4.6
ACH Accendra Health, Inc
5.8
COSM Cosmos Health Inc.
4.5
YI 111, Inc.
6.8
MEDS DataMEDS AI, Inc.
4.3
MCK McKesson Corporation
8.7
HSIC Henry Schein, Inc.
7.3

Valuation data pages: FOCL · SNYR · ACH · COSM · YI · MEDS · MCK · HSIC · COR

Which Other Stocks Score Like VNOV on Quality?

Closest companies to VNOV’s Quality of Company score of 5.6/10, across all industries.

Why Do CirclFi’s 9 Models Disagree on VNOV?

Spread

3547%

Fair Value Range

$0.03 – $1.07

A 3547% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$1.07 (-22.4%)

Most Bearish

ML-RIV

$0.03 (-97.9%)

What Are the Biggest Risks of Buying VNOV Stock?

Model Disagreement

3547% spread signals high variance in projections.

Bearish Consensus

9/9 models suggest overvaluation.

Macro/Sector Risk

Medical Distribution headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View VNOV Data Page →

So Is VNOV (VNOV) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on VNOV at $1.38. 9/9 models flag overvaluation, median fair value sits at $0.46 (-66.7%), and the risk-reward profile appears unfavorable. Quality at 5.6/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. VNOV's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About VNOV Stock?

Should I buy VNOV stock right now?

Based on CirclFi's multi-model analysis, 0 of 9 models see upside for VNOV at $1.38. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in VNOV?

Key risks include: wide model disagreement (3547% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Distribution companies. Always diversify and consult a financial advisor.

How does VNOV compare to its competitors?

Among Medical Distribution peers, VNOV holds a Quality Score of 5.6/10. Comparable companies include FOCL (QOC 5.8), SNYR (QOC 4.6), ACH (QOC 5.8). The relative ranking helps investors identify whether VNOV offers better fundamental quality than alternatives in the same sector.

Is VNOV a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VNOV's Quality Score of 5.6/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy VNOV at?

CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.03 to $1.07. At $1.38, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for VNOV.

View VNOV Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →